Results 171 to 180 of about 2,813,394 (308)

Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS)

open access: yesJournal of Inflammation Research
Dacheng Xiong,1,2 Huixian Geng,1,2 Xuechun Lv,1,2 Shuqi Wang,1,2 Lijing Jia1,2 1Department of Intensive Care Medicine, Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Intensive Care Medicine, Hebei General Hospital ...
Xiong D, Geng H, Lv X, Wang S, Jia L
doaj  

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

open access: yesAging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss   +12 more
wiley   +1 more source

C9orf72 in myeloid cells prevents an inflammatory response to microbial glycogen. [PDF]

open access: yesCell Rep
McCourt B   +10 more
europepmc   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

open access: yesAging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel   +4 more
wiley   +1 more source

Maternal obesity induces activator protein 1-mediated inflammatory response to impair embryonic neurogenesis. [PDF]

open access: yesJ Physiol
Chen LW   +9 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Can evolutionary immunology decode micro and nanoplastic challenges?

open access: yesFrontiers in Immunology
Andi Alijagic   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy